The Evolving Treatment Landscape in Hepatocellular Carcinoma: New Agents and the Role of Biomarkers in Second-Line Treatment

 

 

PROGRAM OVERVIEW

Hepatocellular carcinoma (HCC) is a serious tumor type associated with substantial morbidity and mortality. Yet, for more than 10 years, the multikinase inhibitor sorafenib was the only systemic therapy approved by the U.S. Food & Drug Administration (FDA) for the treatment of HCC. Since 2017, however, six additional agents have received FDA approval as second-line HCC therapy. Given the recent expansion of HCC systemic therapy options, renewed educational endeavors are clearly needed.

The discovery and implementation of biomarkers to predict the efficacy and safety of new agents remain a critical challenge in HCC. Data shows that patients with HCC whose alpha-fetoprotein (AFP) level is ≥400 ng/mL have significantly worse outcomes than do such patients whose AFP level is <400 ng/mL. In recent years, AFP has been used to guide HCC therapeutic selection and monitoring. Understanding the clinical utility of therapies that are efficacious in a patient population with high AFP, and positioning of those therapies, is an important educational need.

The goals of this Twitter-based Plot-Your-Own-Course continuing medical education (CME) activity are to provide clinicians with current, clinically applicable information on the evolving treatment landscape in HCC, with a focus on the efficacy and safety of available agents in the second-line setting, the management of treatment-related adverse events, and the application of research on predictive biomarkers to guide treatment decision-making.

 

FACULTY

Ghassan Abou-Alfa, MD, MBA
Professor and Attending Physician
Department of Medicine
Memorial Sloan Kettering Cancer Center
Weill Medical College, Cornell University
New York, New York

 

Release date: February 24, 2020
Expiration date: February 24, 2021
Estimated time to complete activity: 30 minutes

 

TARGET AUDIENCE

This educational activity is intended for medical oncologists, interventional radiologists, radiologists, gastroenterologists, hepatologists, and oncology advanced practice providers, as well as nurses and other professionals involved in managing patients with HCC.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Discuss efficacy and safety data from key clinical trials evaluating the use of new agents in the second-line HCC treatment setting​
  • Implement strategies to identify, monitor, and manage treatment-related AEs and improve adherence in patients with HCC​
  • Evaluate the potential role of biomarkers in patients with HCC
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of February 24, 2020 through February 24, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or info@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Ghassan Abou-Alfa, MD, MBA
Consulting Fees: 3DMedcare, Agios, Alignmed, Amgen, Antengene, Aptus, Aslan, Astellas, Astra Zeneca, Bayer, Beigene, Bioline, BMS, Boston Scientifc, Bridgebio, Carsgen, Celgene, Casi, Cipla,CytomX, Daiichi, Debio, Delcath, Eisai, Exelixis, Flatiron, Genoscience, Halozyme, Hengrui, Incyte, Inovio, Ipsen, Jazz, Jansen, Klus, Kyowa Kirin, LAM, Lilly, Loxo, Merck, Mina, Novella, Onxeo, PCI Biotech, Pfizer, Pieris, QED, Redhill, Sanofi, Servier, Silenseed, Sillajen, Sobi, Targovax, Tekmira,Twoxar, Vicus, Yakult, Yiviva

Contracted Research: ActaBiologica, Agios, Array, Astra Zeneca, Bayer, Beigene, BMS, Casi, Celgene, Exelixis, Genentech, Halozyme, Incyte, Lilly, Mabvax, Novartis, OncoQuest, Polaris Puma, QED, Roche

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Windows 98, 2000, XP, 2003, Vista, and 7
Internet Explorer 6/7
Firefox 2
Mozilla 1.7 or higher
Netscape 8.1 or higher
Flash Player 10

Mac OS X 10.3, 10.4
Safari 1.3 (Mac OS 10.3)
Safari 2.0 or higher (Mac OS 10.4)
Firefox 2
Flash Player 10
Use of Internet Explorer browser is not recommended.

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

 

Continue to Pretest